menadione + mitomycin c

The combination of menadione and mitomycin C is a chemotherapeutic regimen that has been studied for the treatment of various cancers, particularly lung cancer. This combination was designed as an approach to overcome thiol-mediated resistance to alkylating agent chemotherapy, as menadione (a vitamin K analog) lowers intracellular pools of reduced glutathione (GSH)[1][2]. ## Mechanism of Action Menadione functions by lowering intracellular pools of reduced glutathione, which can mediate resistance to alkylating agents. Mitomycin C is an antineoplastic antibiotic that works as a DNA crosslinking agent, inhibiting DNA synthesis by cross-linking the complementary strands of the DNA double helix[3][5]. This combination was specifically designed to enhance the effectiveness of mitomycin C by reducing cellular defense mechanisms against it. ## Clinical Studies A phase II trial of this combination was conducted in 23 patients with advanced lung cancer. The treatment regimen consisted of menadione (2.5 gm/m² as a continuous intravenous infusion over 48 hours) followed by mitomycin C (10-20 mg/m² IV bolus) administered every 4 to 6 weeks[1]. The study showed that 9% of patients had objective responses, with response durations of 3.5 months and 13 months respectively. Additionally, 4 patients developed short unconfirmed responses[1]. A phase I study established that the maximum tolerated dose of menadione was 2.5 g/m² (as higher doses caused hemolysis), and recommended a combination of menadione at 2.5 g/m² as a continuous intravenous infusion with mitomycin C at 15 mg/m² for further study in solid tumors[2]. ## Side Effects The combination was generally well-tolerated with some notable exceptions: - Hematologic toxicity (31% of treatment courses had grade 3 or 4 toxicity) - Hemolytic anemia - Interstitial pneumonitis (in one patient) - Cardiac events (two patients developed decreased left ventricular ejection fraction)[1] - Dose-dependent hemolysis with higher doses of menadione[2]